Related Experiment Video

Updated: Feb 6, 2026

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

3.0K

Arginine-lowering enzymes against cancer: a technocommercial analysis through patent landscape

Rakhi Dhankhar1, Pooja Gulati1, Sanjay Kumar1

  • 1a Medical Microbiology and Bioprocess Technology Laboratory, Department of Microbiology , Maharshi Dayanand University , Rohtak , Haryana , India.

Expert Opinion on Therapeutic Patents
|August 10, 2018
PubMed
Abstract

Insights

Arginine-lowering enzymes (ALEs), particularly arginine deiminase (ADI), show promise in cancer biotherapy. Clinical trials are exploring ADI-based treatments for various cancers, with ADI-PEG20 demonstrating effectiveness in combination therapies.

Area of Science:

  • Oncology
  • Biotechnology
  • Enzyme Therapy

Background:

  • Rising cancer incidence fuels demand for novel biotherapies.
  • Arginine-lowering enzymes (ALEs) offer a targeted approach to cancer treatment.
  • Arginine deiminase (ADI) is a key ALE with significant therapeutic potential.

Purpose of the Study:

  • To analyze patents and clinical trials in ALE-based cancer therapy.
  • To identify technology trends, key players, and inventors in this field.
  • To assess the therapeutic potential of ALEs, especially ADI, in oncology.

Main Methods:

  • Review of patents and clinical trial data related to ALEs.
  • Analysis of technological advancements and market trends.
  • Evaluation of ADI's efficacy in preclinical and clinical studies.

Main Results:

  • Arginine deiminase (ADI) emerges as the most promising ALE for cancer treatment.
  • ADI-based therapies show potential for liver, skin, lung, gastrointestinal, and blood cancers.
  • ADI-PEG20 demonstrates efficacy in combination therapy, particularly as a first-line treatment.

Conclusions:

  • Arginine deiminase (ADI) represents a significant advancement in cancer biotherapy.
  • Ongoing clinical studies, especially combinatorial approaches, are crucial for ADI-PEG20's market entry.
  • Polaris Group leads in the development of ADI as a therapeutic agent for a multi-million dollar cancer market.
Keywords:
ADI-PEG20Arginine-lowering enzymesPEGylationPolaris Groupcancer

More Related Videos

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

1.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Related Concept Videos

Vapor Pressure Lowering03:28

Vapor Pressure Lowering

The equilibrium vapor pressure of a liquid is the pressure exerted by its gaseous phase when vaporization and condensation are occurring at equal rates:
31.3K
Enzymes02:34

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
94.9K
Enzyme Kinetics01:19

Enzyme Kinetics

Enzymes speed up reactions by lowering the activation energy of the reactants. The speed at which the enzyme turns reactants into products is called the rate of reaction. Several factors impact the rate of reaction, including the number of available reactants. Enzyme kinetics is the study of how an enzyme changes the rate of a reaction.
Scientists typically study enzyme kinetics with a fixed amount of enzyme in the controlled environment of a test tube. When more reactant, or substrate, is...
104.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
769
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.7K